Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Postoperative Pain in VATS
NCT02886429Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2016
- Primary completion
- Aug 2018
- Countries
- 1
- Sponsor
- Assiut University
- Modality
- Small Molecules
- Drugs
- dexmedetomidine
- Conditions
- postoperative pain
01
Overview
Phase 2, randomised, double-blind trial of dexmedetomidine in postoperative pain (2 arms), sponsored by Assiut University. Primary endpoint: Post-thoracotomy pain at 24 hours. Started Aug 2016; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Bupivacaine Control
Ultrasound guided paravertebral block with bupivacaine 0.5% (0.3ml/kg).
Dexmedetomidine Experimental
Ultrasound guided paravertebral block with bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg).
03
Who it enrols
Adult patients (18-60 years) with ASA physical status I-III undergoing elective video-assisted thoracoscopy surgery. Patients with liver or renal impairment, allergy to study drugs, coagulopathy, anticoagulation therapy, or infection at the injection site are excluded.
04
Endpoints
Primary
Post-thoracotomy pain
Secondary
Pulmonary function tests
Rescue analgesia consumption
Sedation score
Nausea and vomiting
Beyond the preview
Go deeper on NCT02886429.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02886429.